DENVER, Colo., Mar 20, 2025 (247marketnews.com) – Eyenovia (NASDAQ:EYEN) announced signing a non-binding letter of intent (LOI) for a reverse merger with Betaliq, a clinical-stage pharma focused on glaucoma solutions. If sealed, this union would birth a new eye care powerhouse, blending Betaliq’s EyeSol water-free drug delivery tech with Eyenovia’s cutting-edge Optejet system.
Michael Rowe, Eyenovia’s CEO, commented, “Following a review of strategic alternatives that we initiated in January, I, along with my fellow Board members, concluded that continuing the negotiation of this potential merger with Betaliq is in the best interests of our company, our team members, patients and shareholders. Under a combined new company, if the transaction is completed, our existing products could continue to be marketed to ophthalmologists and optometrists, while the combination of the EyeSol and Optejet technologies has the potential to create a platform that could fundamentally improve how topical eye medications and products are administered. We look forward to working with the Betaliq team on the completion of due diligence and the negotiation and potential execution of a definitive merger agreement in the coming weeks.”
Leveraging two FDA-approved technologies to tackle glaucoma and beyond. Betaliq’s EyeSol—already powering products like Bausch + Lomb’s MEIBO and Harrow’s VEVYE—brings pinpoint 10-microliter drops and boosted bioavailability. Paired with Optejet’s user-friendly precision could redefine treatment ease and efficacy. The merged entity plans to keep pushing Eyenovia’s FDA-approved lineup, including Mydcombi and Clobetasol Propionate, while in-licensing new products to spark near-term revenue.
Barry Butler, Betaliq’s CEO, added, “This proposed merger with Eyenovia represents a significant opportunity in the eyecare space. The inherent synergies of the EyeSol and Optejet technologies could bring innovative new treatment options to patients with glaucoma as well as other ocular diseases. By leveraging the existing pipelines of Eyenovia and Betaliq with multiple opportunities for pipeline expansion through established partnerships, we believe we can build a leading ophthalmic company.”
With the $8 billion glaucoma market in sight, this merger could catapult both companies.
The post Eyenovia and Betaliq Eye a Game-Changing Merger in Ophthalmic Innovation appeared first on 24/7 MarketNews.
